Fundraising Fox3C Therapeutics
1 known investors
Find your way into 3C Therapeutics
Sign up to see every warm intro you have to 3C Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 3C Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
3C Therapeutics develops therapeutics using targeted protein degradation, centered on a proprietary modular Degrader-Antibody Conjugate (DAC) platform (TriCore) that delivers intracellular protein degraders via monoclonal antibodies. The company focuses on drug discovery for previously inaccessible targets through a ligand-independent conjugation approach.
Founders & leadership
DP
David PerrinCo-Founder & Scientific Advisor
DW
Dan WattierChief Executive OfficerHe has held executive roles at multiple biotech companies and has experience in R&D leadership, commercialization, and pharma-biotech partnerships.
TP
Tony PolverinoFractional CSO
DW
David WoodChief Financial Officer
Investors · 1
Frequently asked questions
- What does 3C Therapeutics do?
- 3C Therapeutics develops therapeutics using targeted protein degradation, centered on a proprietary modular Degrader-Antibody Conjugate (DAC) platform (TriCore) that delivers intracellular protein degraders via monoclonal antibodies. The company focuses on drug discovery for previously inaccessible targets through a ligand-independent conjugation approach.
- Who founded 3C Therapeutics?
- 3C Therapeutics was founded by David Perrin, Benjamin Noichl.
- Who are 3C Therapeutics's investors?
- 3C Therapeutics's investors include Innovation UBC.